Macquarie Group’s OptimizeRx OPRX Stock Holding History

Macquarie Group’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,262	Closed	-$2.16M	–	2637
2021 Q3	$2.16M	Sell	25,262 -9,738	-28%	-$611K	﹤0.01%	1365
2021 Q2	$2.17M	Sell	35,000 -3,982	-10%	-$203K	﹤0.01%	1394
2021 Q1	$1.9M	Buy	38,982 +38,182	+4,773%	+$1.84M	﹤0.01%	1219
2020 Q4	$25K	Buy	+800	New	+$19.6K	﹤0.01%	2176

Other funds holding OPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

Macquarie Group's OPRX Position: Q4 2021 in Review

Macquarie Group sold out of OptimizeRx (OPRX) in Q4 2021, closing a stake of 25,262 shares — an estimated $2.16M sold.

Macquarie Group first reported a position in OPRX in Q4 2020 and held it in 4 quarters. The position peaked at $2.17M in Q2 2021. 180 funds tracked by Wall St. Rank hold OPRX as of Q4 2021.

Macquarie Group reported no remaining OptimizeRx position as of Q4 2021 after selling out during the quarter.
Macquarie Group sold 25,262 OptimizeRx shares in Q4 2021, an estimated $2.16M.
Macquarie Group first reported a position in OptimizeRx in Q4 2020 and held it in 4 quarters.
Macquarie Group's OptimizeRx position peaked at $2.17M in Q2 2021.
180 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2021.

Based on Macquarie Group's 13F filing for Q4 2021, filed 11 Feb 2022.